INmune Bio Inc (INMB) - Total Liabilities
Based on the latest financial reports, INmune Bio Inc (INMB) has total liabilities worth $7.98 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
INmune Bio Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how INmune Bio Inc's total liabilities have evolved over time, based on quarterly financial data. See INMB current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
INmune Bio Inc Competitors by Total Liabilities
The table below lists competitors of INmune Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NXT Energy Solutions Inc
TO:SFD
|
Canada | CA$4.08 Million |
|
Kunming Longjin Pharmaceutical Co Ltd
SHE:002750
|
China | CN¥69.96 Million |
|
InspireMD Inc
NASDAQ:NSPR
|
USA | $12.85 Million |
|
Novacyt
PA:ALNOV
|
France | €16.94 Million |
|
Hudson Global Inc
NASDAQ:HSON
|
USA | $15.45 Million |
|
Power Solution Technologies Public Company Limited
BK:PSTC
|
Thailand | ฿1.67 Billion |
|
PTL LTD Ordinary Shares
NASDAQ:PTLE
|
USA | $425.73K |
|
Union Corporation
KO:000910
|
Korea | ₩212.48 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down INmune Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of INmune Bio Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how INmune Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for INmune Bio Inc (2015–2024)
The table below shows the annual total liabilities of INmune Bio Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $7.46 Million | -60.42% |
| 2023-12-31 | $18.86 Million | -13.04% |
| 2022-12-31 | $21.69 Million | +9.99% |
| 2021-12-31 | $19.72 Million | +936.80% |
| 2020-12-31 | $1.90 Million | +121.02% |
| 2019-12-31 | $860.54K | +4.46% |
| 2018-12-31 | $823.77K | +165.97% |
| 2017-12-31 | $309.72K | -48.45% |
| 2016-12-31 | $600.81K | +1853.85% |
| 2015-12-31 | $30.75K | -- |
About INmune Bio Inc
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of pati… Read more